<p>Janux Therapeutics（纳斯达克代码：JANX - 获取免费报告）的股票在周二的研究报告中被 Wedbush 的投资分析师重新给予了 “跑赢大盘” 的评级，RTT News 报道。他们目前对该股票的目标价为 45.00 美元，低于之前的 76.00 美元。Wedbush 的目标价暗示该公司当前价格有 183.73% 的潜在上涨空间。</p>
<p>其他几位分析师也对 JANX 发表了评论。Weiss Ratings 在 10 月 8 日的研究报告中重新给予 Janux Therapeutics 股票 “卖出（d-）” 评级。Piper Sandler 在 8 月 18 日的研究报告中开始覆盖 Janux Therapeutics 股票。他们为该公司设定了 “增持” 评级和 42.00 美元的目标价。美国银行在周二的研究报告中将 Janux Therapeutics 的目标价从 58.00 美元下调至 49.00 美元，并给予该公司 “买入” 评级。巴克莱在 11 月 7 日的研究报告中将 Janux Therapeutics 的目标价从 47.00 美元上调至 48.00 美元，并给予该股票 “增持” 评级。最后，HC Wainwright 在周二的研究报告中将 Janux Therapeutics 的目标价从 70.00 美元下调至 45.00 美元，并给予该公司 “买入” 评级。一位股票研究分析师给予该股票 “强烈买入” 评级，十四位分析师给予 “买入” 评级，两位分析师给予 “持有” 评级，一位分析师给予 “卖出” 评级。根据 MarketBeat.com 的数据，该公司的平均评级为 “适度买入”，共识目标价为 67.36 美元。</p>
<p>获取 <strong>Janux Therapeutics</strong> 警报：</p>
<p><strong>获取我们最新的 JANX 股票报告</strong></p>
<h2>Janux Therapeutics 股票下跌 53.3%</h2>
<p>在周二的交易中，JANX 股票下跌了 18.13 美元，跌至 15.86 美元。该公司的交易量为 15,930,781 股，而其平均交易量为 1,150,156 股。Janux Therapeutics 的 52 周低点为 15.77 美元，52 周高点为 71.71 美元。该公司的 50 日简单移动平均线为 27.15 美元，200 日简单移动平均线为 25.37 美元。该公司的市值为 9.5398 亿美元，市盈率为-9.44，贝塔值为 2.82。</p>
<p>Janux Therapeutics（纳斯达克代码：JANX - 获取免费报告）最近于 11 月 6 日发布了其财报。该公司报告本季度每股收益为（0.39 美元），超出分析师一致预期的（0.60 美元）0.21 美元。该公司本季度的收入为 1000 万美元，而一致预期为 307 万美元。卖方分析师预测 Janux Therapeutics 在当前年度的每股收益将为-1.38 美元。</p>
<h2>Janux Therapeutics 的内部买卖</h2>
<p>在其他 Janux Therapeutics 的新闻中，内部人士 Andrew Hollman Meyer 在 10 月 28 日（星期二）出售了该公司 16,665 股股票。该股票以平均价格 30.06 美元出售，总价值为 500,949.90 美元。出售后，该内部人士直接持有该公司 82,139 股股票，价值约为 2,469,098.34 美元。这笔交易代表了他们持股比例的 16.87% 的减少。该出售在向证券交易委员会提交的文件中披露，文件可通过此链接访问。29.40% 的股票目前由公司内部人士持有。</p>
<h2>对 Janux Therapeutics 的对冲基金看法</h2>
<p>一些对冲基金最近对该公司的持仓进行了调整。Alyeska Investment Group L.P.在第三季度将其在 Janux Therapeutics 的持仓提高了 64.2%。Alyeska Investment Group L.P.现在拥有 424,845 股该公司的股票，价值 10,383,000 美元，此前在上个季度增持了 166,167 股。Verition Fund Management LLC 在第三季度将其在 Janux Therapeutics 的持仓提高了 240.3%。Verition Fund Management LLC 现在拥有 40,731 股该公司的股票，价值 995,000 美元，此前在上个季度增持了 28,761 股。Jain Global LLC 在第三季度购买了 Janux Therapeutics 的新头寸，价值 241,000 美元。Orbimed Advisors LLC 在第三季度将其在 Janux Therapeutics 的持仓提高了 45.9%。Orbimed Advisors LLC 现在拥有 1,766,100 股该公司的股票，价值 43,163,000 美元，此前在上个季度增持了 555,800 股。最后，ADAR1 Capital Management LLC 在第三季度将其在 Janux Therapeutics 的持仓提高了 7.4%。ADAR1 Capital Management LLC 现在拥有 351,032 股该公司的股票，价值 8,579,000 美元，此前在上个季度增持了 24,044 股。机构投资者和对冲基金持有该公司 75.39% 的股票。</p>
<h2>关于 Janux Therapeutics</h2>
<p>（获取免费报告）</p>
<p>Janux Therapeutics, Inc.是一家临床阶段的生物制药公司，开发基于肿瘤激活 T 细胞连接器（TRACTr）和肿瘤激活免疫调节剂（TRACIr）平台技术的免疫疗法，以治疗患有癌症的患者。该公司的临床候选药物包括 JANX007，一种前列腺特异性膜抗原或 PSMA-TRACTr，目前正在进行针对转移性去势抵抗性前列腺癌（mCRPC）和其他肿瘤血管的 1 期临床试验；以及 JANX008，一种表皮生长因子受体或 EGFR-TRACTr，目前正在进行针对多种实体癌症的 1 期临床试验，包括结直肠癌、头颈部鳞状细胞癌、非小细胞肺癌和肾细胞癌。</p>
<h2>了解更多</h2>
<ul>
<li>我们更看好的五只股票比 Janux Therapeutics 更好</li>
<li>拥有债券的风险</li>
<li>华尔街的沉睡巨人：亚马逊即将觉醒吗？</li>
<li>现在购买的三只最佳金融科技股票</li>
<li>云端的绝杀：ServiceNow 的购物狂欢</li>
<li>罗素 2000 指数，投资者如何利用它进行盈利交易</li>
<li>在 MSCI 退市风波中对 MSTR 的逆向投资案例</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9SkFOWA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9SkFOWA"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，旨在为读者提供最快的报道和公正的覆盖。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com.</em></p>
<h2>你现在应该投资 1,000 美元在 Janux Therapeutics 吗？</h2>
<p>在考虑 Janux Therapeutics 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而 Janux Therapeutics 并不在名单上。</p>
<p>虽然 Janux Therapeutics 目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

JANX

<p>Wedbush 重申了对 Janux Therapeutics（NASDAQ:JANX）的 “跑赢大盘” 评级，目标价格修订为 45.00 美元，较之前的 76.00 美元下调，暗示潜在上涨空间为 183.73%。其他分析师的评级则各有不同，有些分析师下调了目标价格。Janux 的股价下跌了 53.3%，至 15.86 美元。该公司报告了超出预期的收益和收入。还注意到内部交易和对冲基金活动</p>

<p>Janux Therapeutics (NASDAQ:JANX - Get Free Report)'s stock had its &#34;outperform&#34; rating reissued by investment analysts at Wedbush in a research note issued on Tuesday,RTT News reports. They presently have a $45.00 target price on the stock, down from their previous target price of $76.00. Wedbush's target price suggests a potential upside of 183.73% from the company's current price.</p>
<div class="lb-trans"><p>Janux Therapeutics（纳斯达克代码：JANX - 获取免费报告）的股票在周二的研究报告中被 Wedbush 的投资分析师重新给予了 “跑赢大盘” 的评级，RTT News 报道。他们目前对该股票的目标价为 45.00 美元，低于之前的 76.00 美元。Wedbush 的目标价暗示该公司当前价格有 183.73% 的潜在上涨空间。</p>
</div><p>Several other analysts have also commented on JANX. Weiss Ratings reissued a &#34;sell (d-)&#34; rating on shares of Janux Therapeutics in a research report on Wednesday, October 8th. Piper Sandler started coverage on shares of Janux Therapeutics in a research report on Monday, August 18th. They set an &#34;overweight&#34; rating and a $42.00 target price for the company. Bank of America lowered their target price on shares of Janux Therapeutics from $58.00 to $49.00 and set a &#34;buy&#34; rating for the company in a research note on Tuesday. Barclays upped their price target on Janux Therapeutics from $47.00 to $48.00 and gave the stock an &#34;overweight&#34; rating in a research report on Friday, November 7th. Finally, HC Wainwright lowered their price objective on Janux Therapeutics from $70.00 to $45.00 and set a &#34;buy&#34; rating for the company in a research report on Tuesday. One equities research analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company has an average rating of &#34;Moderate Buy&#34; and a consensus target price of $67.36.</p>
<div class="lb-trans"><p>其他几位分析师也对 JANX 发表了评论。Weiss Ratings 在 10 月 8 日的研究报告中重新给予 Janux Therapeutics 股票 “卖出（d-）” 评级。Piper Sandler 在 8 月 18 日的研究报告中开始覆盖 Janux Therapeutics 股票。他们为该公司设定了 “增持” 评级和 42.00 美元的目标价。美国银行在周二的研究报告中将 Janux Therapeutics 的目标价从 58.00 美元下调至 49.00 美元，并给予该公司 “买入” 评级。巴克莱在 11 月 7 日的研究报告中将 Janux Therapeutics 的目标价从 47.00 美元上调至 48.00 美元，并给予该股票 “增持” 评级。最后，HC Wainwright 在周二的研究报告中将 Janux Therapeutics 的目标价从 70.00 美元下调至 45.00 美元，并给予该公司 “买入” 评级。一位股票研究分析师给予该股票 “强烈买入” 评级，十四位分析师给予 “买入” 评级，两位分析师给予 “持有” 评级，一位分析师给予 “卖出” 评级。根据 MarketBeat.com 的数据，该公司的平均评级为 “适度买入”，共识目标价为 67.36 美元。</p>
</div><p>Get <strong>Janux Therapeutics</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Janux Therapeutics</strong> 警报：</p>
</div><p><strong>Get Our Latest Stock Report on JANX</strong></p>
<div class="lb-trans"><p><strong>获取我们最新的 JANX 股票报告</strong></p>
</div><h2>Janux Therapeutics Stock Down 53.3%</h2>
<div class="lb-trans"><h2>Janux Therapeutics 股票下跌 53.3%</h2>
</div><p>JANX stock traded down $18.13 during trading on Tuesday, hitting $15.86. The company had a trading volume of 15,930,781 shares, compared to its average volume of 1,150,156. Janux Therapeutics has a 52-week low of $15.77 and a 52-week high of $71.71. The company has a 50 day simple moving average of $27.15 and a 200-day simple moving average of $25.37. The firm has a market capitalization of $953.98 million, a P/E ratio of -9.44 and a beta of 2.82.</p>
<div class="lb-trans"><p>在周二的交易中，JANX 股票下跌了 18.13 美元，跌至 15.86 美元。该公司的交易量为 15,930,781 股，而其平均交易量为 1,150,156 股。Janux Therapeutics 的 52 周低点为 15.77 美元，52 周高点为 71.71 美元。该公司的 50 日简单移动平均线为 27.15 美元，200 日简单移动平均线为 25.37 美元。该公司的市值为 9.5398 亿美元，市盈率为-9.44，贝塔值为 2.82。</p>
</div><p>Janux Therapeutics (NASDAQ:JANX - Get Free Report) last issued its earnings results on Thursday, November 6th. The company reported ($0.39) EPS for the quarter, topping analysts' consensus estimates of ($0.60) by $0.21. The company had revenue of $10.00 million during the quarter, compared to the consensus estimate of $3.07 million. Sell-side analysts forecast that Janux Therapeutics will post -1.38 earnings per share for the current year.</p>
<div class="lb-trans"><p>Janux Therapeutics（纳斯达克代码：JANX - 获取免费报告）最近于 11 月 6 日发布了其财报。该公司报告本季度每股收益为（0.39 美元），超出分析师一致预期的（0.60 美元）0.21 美元。该公司本季度的收入为 1000 万美元，而一致预期为 307 万美元。卖方分析师预测 Janux Therapeutics 在当前年度的每股收益将为-1.38 美元。</p>
</div><h2>Insider Buying and Selling at Janux Therapeutics</h2>
<div class="lb-trans"><h2>Janux Therapeutics 的内部买卖</h2>
</div><p>In other Janux Therapeutics news, insider Andrew Hollman Meyer sold 16,665 shares of the firm's stock in a transaction that occurred on Tuesday, October 28th. The stock was sold at an average price of $30.06, for a total value of $500,949.90. Following the sale, the insider directly owned 82,139 shares of the company's stock, valued at approximately $2,469,098.34. This trade represents a 16.87% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities &amp; Exchange Commission, which is accessible through this hyperlink. 29.40% of the stock is currently owned by company insiders.</p>
<div class="lb-trans"><p>在其他 Janux Therapeutics 的新闻中，内部人士 Andrew Hollman Meyer 在 10 月 28 日（星期二）出售了该公司 16,665 股股票。该股票以平均价格 30.06 美元出售，总价值为 500,949.90 美元。出售后，该内部人士直接持有该公司 82,139 股股票，价值约为 2,469,098.34 美元。这笔交易代表了他们持股比例的 16.87% 的减少。该出售在向证券交易委员会提交的文件中披露，文件可通过此链接访问。29.40% 的股票目前由公司内部人士持有。</p>
</div><h2>Hedge Funds Weigh In On Janux Therapeutics</h2>
<div class="lb-trans"><h2>对 Janux Therapeutics 的对冲基金看法</h2>
</div><p>A number of hedge funds have recently made changes to their positions in the company. Alyeska Investment Group L.P. lifted its position in shares of Janux Therapeutics by 64.2% in the third quarter. Alyeska Investment Group L.P. now owns 424,845 shares of the company's stock valued at $10,383,000 after acquiring an additional 166,167 shares in the last quarter. Verition Fund Management LLC raised its stake in Janux Therapeutics by 240.3% in the 3rd quarter. Verition Fund Management LLC now owns 40,731 shares of the company's stock valued at $995,000 after purchasing an additional 28,761 shares during the last quarter. Jain Global LLC purchased a new position in Janux Therapeutics in the 3rd quarter valued at $241,000. Orbimed Advisors LLC boosted its stake in Janux Therapeutics by 45.9% during the 3rd quarter. Orbimed Advisors LLC now owns 1,766,100 shares of the company's stock worth $43,163,000 after purchasing an additional 555,800 shares during the last quarter. Finally, ADAR1 Capital Management LLC grew its holdings in shares of Janux Therapeutics by 7.4% during the third quarter. ADAR1 Capital Management LLC now owns 351,032 shares of the company's stock worth $8,579,000 after buying an additional 24,044 shares in the last quarter. Institutional investors and hedge funds own 75.39% of the company's stock.</p>
<div class="lb-trans"><p>一些对冲基金最近对该公司的持仓进行了调整。Alyeska Investment Group L.P.在第三季度将其在 Janux Therapeutics 的持仓提高了 64.2%。Alyeska Investment Group L.P.现在拥有 424,845 股该公司的股票，价值 10,383,000 美元，此前在上个季度增持了 166,167 股。Verition Fund Management LLC 在第三季度将其在 Janux Therapeutics 的持仓提高了 240.3%。Verition Fund Management LLC 现在拥有 40,731 股该公司的股票，价值 995,000 美元，此前在上个季度增持了 28,761 股。Jain Global LLC 在第三季度购买了 Janux Therapeutics 的新头寸，价值 241,000 美元。Orbimed Advisors LLC 在第三季度将其在 Janux Therapeutics 的持仓提高了 45.9%。Orbimed Advisors LLC 现在拥有 1,766,100 股该公司的股票，价值 43,163,000 美元，此前在上个季度增持了 555,800 股。最后，ADAR1 Capital Management LLC 在第三季度将其在 Janux Therapeutics 的持仓提高了 7.4%。ADAR1 Capital Management LLC 现在拥有 351,032 股该公司的股票，价值 8,579,000 美元，此前在上个季度增持了 24,044 股。机构投资者和对冲基金持有该公司 75.39% 的股票。</p>
</div><h2>About Janux Therapeutics</h2>
<div class="lb-trans"><h2>关于 Janux Therapeutics</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.</p>
<div class="lb-trans"><p>Janux Therapeutics, Inc.是一家临床阶段的生物制药公司，开发基于肿瘤激活 T 细胞连接器（TRACTr）和肿瘤激活免疫调节剂（TRACIr）平台技术的免疫疗法，以治疗患有癌症的患者。该公司的临床候选药物包括 JANX007，一种前列腺特异性膜抗原或 PSMA-TRACTr，目前正在进行针对转移性去势抵抗性前列腺癌（mCRPC）和其他肿瘤血管的 1 期临床试验；以及 JANX008，一种表皮生长因子受体或 EGFR-TRACTr，目前正在进行针对多种实体癌症的 1 期临床试验，包括结直肠癌、头颈部鳞状细胞癌、非小细胞肺癌和肾细胞癌。</p>
</div><h2>Read More</h2>
<div class="lb-trans"><h2>了解更多</h2>
</div><ul>
<li>Five stocks we like better than Janux Therapeutics</li>
<li>The Risks of Owning Bonds</li>
<li>Wall Street’s Sleeping Giant: Is Amazon About to Wake Up?</li>
<li>The 3 Best Fintech Stocks to Buy Now</li>
<li>Checkmate in the Cloud: ServiceNow's Shopping Spree</li>
<li>Russell 2000 Index, How Investors Use it For Profitable Trading</li>
<li>The Contrarian Case for MSTR Amid MSCI Delisting Debacle</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票比 Janux Therapeutics 更好</li>
<li>拥有债券的风险</li>
<li>华尔街的沉睡巨人：亚马逊即将觉醒吗？</li>
<li>现在购买的三只最佳金融科技股票</li>
<li>云端的绝杀：ServiceNow 的购物狂欢</li>
<li>罗素 2000 指数，投资者如何利用它进行盈利交易</li>
<li>在 MSCI 退市风波中对 MSTR 的逆向投资案例</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9SkFOWA" alt="" original-src="https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx?Prefix=NASDAQ&amp;Symbol=JANX"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，旨在为读者提供最快的报道和公正的覆盖。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Janux Therapeutics Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Janux Therapeutics 吗？</h2>
</div><p>Before you consider Janux Therapeutics, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Janux Therapeutics 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Janux Therapeutics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而 Janux Therapeutics 并不在名单上。</p>
</div><p>While Janux Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Janux Therapeutics 目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

在 Wedbush，Janux Therapeutics（JANX）的跑赢大盘评级被再次确认